Agrochemicals company Insecticides (India) announced Q2FY25 results Revenue from Operations: Rs 627 crore compared to Rs 696 crore during Q2FY24, change -10%. EBITDA: Rs 90 crore compared to Rs 82 crore during Q2FY24, change 9%. EBITDA margin: 14.3% for Q2FY25. PAT: Rs 61 crore compared to Rs 53 crore during Q2FY24, change 16%. PAT margin: 9.8% for Q2FY25. Rajesh Aggarwal, MD of Insecticides (India), said: “We are pleased to announce our Q2 & H1FY25 results, reflecting healthy performance across key financial and operational metrics. Achieving Net Profit of Rs 111 crore in first half, we have already surpassed the full FY24 profit of Rs 102 crore—a testament to the strength of our strategy and execution. Our focus will remain on driving higher growth in premium products, underpinned by New Product Launches, more extensive demand generation and brand-building initiatives. During the quarter, we observed firming up of raw material prices although excessive and continued rainfall resulted in lower pest infestation. The farmers delayed their spraying schedule, which adversely impacted revenue growth for the Company. The monsoon has been marking India’s wettest monsoon in four years, with rainfall exceeding 100% of the long term average, resulting an increase in sowing for Kharif crop and promising outlook for Rabi season This quarter, we have launched an innovative 9(3) herbicide for maize, Torry Super based on SPF technology, developed by in-house R&D; team. SPF technology of Torry Super will provide faster results and long duration control of weeds. We are getting an overwhelming response of Torry Super in maize of Rabi season in the southern & western part of the country, where season has already begun. Our strategic emphasis remains on premiumisation, capital efficiency and surplus cash generation with visible improvement across profitability, working capital & ROCE, ROE. In a move to reward our shareholders, we completed a buyback of 500,000 fully paid-up equity shares at Rs 1,000 each, amounting to Rs 50 crore, through internal accrual. With favorable market conditions and intense focus on premiumisation, we expect healthy profit growth and leaner balance sheet as we progress into this financial year.“ Result PDF